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Memory is our ability to store and remember past experiences; it is the result of changes in neuronal circuits of specific brain areas as
the hippocampus. During memory formation, neurons integrate their functions and increase the strength of their connections, so
that synaptic plasticity is improved and consolidated. All these processes recruit several proteins at the synapses, whose expression
is highly regulated by DNAmethylation and histone tails posttranslational modifications. Steroids are known to influence memory
process, and, among them, neurosteroids are implicated in neurodegenerative disease related to memory loss and cognitive
impairment.The epigenetic control of neurosteroids involvement in memory formation andmaintenance could represent the basis
for neuroregenerative therapies.
1. Introduction
The ability of an individual to remember past experiences
is due to learning, that is, the acquisition and elaboration
of information, and to memory, namely, the ability to store
and retrieve information. These are distinct, even if closely
related, neural phenomena: learning is slow and hard, as it
requires the transformation of the initially labile information
intomore persistent one, while memory is a rapid process [1].
When we learn, our brain first depicts the new experience
by means of neural representations that, next, need to
be consolidated, through the establishment of a neuronal
network located in specific brain areas. This is crucial to
allow us to rapidly retrieve information starting from stimuli
apparently far from, and distantly associated with, the initial
experience [2]. Here we discuss the main phases of memory
formation and maintenance, with particular attention to the
epigenetic regulation and to the effects of neurosteroids on
memory.
2. Brain Structures Involved in
Memory Processes
Many brain structures cooperate supporting rapid encod-
ing of new information, consolidation and organization of
memory networks: the hippocampus, the amygdala and the
adjacent entorhinal, perirhinal (PRC), and parahippocampal
cortices (PHC), usually known as medial temporal lobe
structures (MTL). For an experience to become amemory, we
need to acquire the information about what we experience,
that is people, objects, and events, and to put them in
a precise spatial location. The anatomical organization of
the brain areas supporting memory is crucial to process
qualitatively different information in a differential manner
[3]. When all the information converges at the hippocampal
level, fixed memories of each specific event are formed
and the event details are processed in the spatial context
in which the memorable event occurred [3]. Usually, in
humans, an increased hippocampal activity is associated
with strong experiences, regardless of the memory process
involved [4]. The hippocampus supports also the retrieval of
the information, originating feedback inputs that come back
to those cortical areas from which inputs arose [2].
3. Memory Encoding, Consolidation,
Storage, and Retrieval
The highly dynamic process of memory formation includes
different phases, fully interconnected: encoding, consolida-
tion, storage, and retrieval. The encoding process begins
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with perception of sensory inputs coming from daily life
experiences. Some aspects of any experienced event get
encoded by means of transformations aimed to create a
permanent memory trace, which is first stored in the MTL
structures. These memory representations are then delivered
to cortical areas more useful to long-term storage, being
protected against the disrupting effect of new incoming
memories [1]. The encoding process is strictly influenced
by particular conditions, for example, positive and nega-
tive emotions: emotionally relevant information is usually
remembered more easily than neutral ones (see [1] for
references). During consolidation, encoded memory traces
gradually transform from an initially vulnerable state to
a more permanent one, determining both what will be
preserved after initial encoding and how long this trace will
be retained without any other modification (reconsolidation)
[5]. Data coming from patients with memory loss revealed
that the hippocampus behaves as a temporary store for new
information, while permanent information storage is related
to the establishment on a broadly distributed cortical network
[6]. As for encoding, consolidation also is influenced by
several different signals: among them glucocorticoids, which
affect consolidation of emotionally arousing experiences, and
sleep, which reinforces memory consolidation by reprocess-
ing initially labilememories in a stable representation suitable
for long-term storage [1, 5]. Storage is due to modifications
in the pattern of synaptic strength in a specific neuronal
circuit involved in the learned behaviour. This phase fulfils
the former hypothesis by Donald Hebb in the 50s that stated
“not a single cell but networks of neurons, which change the
strength of their connections and therefore their input/output
characteristics, can be used to store information” [7]. The
ability to remember information becomes effective in the
retrieval phase, that is, to get back information from storage




The storage of information in the mammalian nervous
system depends on the dynamic formation and stability
of neuronal connections. Neurons located in brain areas
involved in memory processes are highly plastic and respond
to external stimuli modifying their morphology and func-
tions [8]. Neuronal connectivity is strictly dependent on
synaptic strength and synaptic plasticity, which are basic for
learning as well as for short-term and long-term storage of
memories.
Synaptic strength is the amplitude of the postsynaptic
response generated by the activity of a presynaptic neuron.
It is strictly dependent on the amount of neurotransmitters
released in the synaptic cleft and on the type and number
of receptors activated in the synapsis. Any lasting upreg-
ulation or downregulation of synaptic strength is referred
to as synaptic plasticity and represents the main effector
of synaptic functions. As it is crucial for creating func-
tional neuronal connections, synaptic plasticity is a leading
phenomenon especially at the hippocampal level, where it
is essential both for the formation and also for recall of
different kind of memory. Different subregions, populated
with distinct excitatory neurons, can be distinguished in
the mammalian hippocampus [8]. The entorhinal cortex
represents the starting point through which information
enters the hippocampus, then reaching the granular cells of
the dentate gyrus. Neurons of the dentate gyrus send axons
(mossy fibers) to the CA3 pyramidal neurons, which are
connected to CA1 neurons. CA2 area is a small region located
between CA1 and CA3 neurons that receives input from the
dentate gyrus and from the entorhinal cortex and projects
to CA1 pyramidal neurons. The different CA regions possess
intrinsic distinct significance. The CA2 subregion seems to
be involved in the control of social learning in mice, while
CA3 is essential in the encoding of novel information; the
CA3–CA1 synapse is the best example of synaptic plasticity
and is mandatory for the recall processes [8]. Different popu-
lations of inhibitory interneurons are also present in all hip-
pocampal subregions mediating feedback and feedforward
inhibition.
The persistent strengthening of the synapses following
high levels of stimulation is called Long-Term Potentiation
(LTP) and represents the main mechanism for learning
and memory formation. LTP requires cascades of com-
plex molecular events and the coordinated remodelling of
presynaptic and postsynaptic neurons [9]. Although LTP is
extensively investigated since 1970s [10], the understanding
of the transcriptional mechanisms and molecular processes
determining LTP remains incomplete. Two different forms of
LTP have been described, with temporally and mechanisti-
cally distinct phases. One is the short-term LTP (early LTP),
generally lasting less than one hour, which does not require
“de novo” protein synthesis but results from modifications
of preexisting synaptic proteins. The other is long-lasting
LTP (late LTP), requiring activity-induced protein synthesis
and gene transcription and lasting many hours to week
(see [11] for reference). Proteins induced in late LTP relate
to signal transduction, organization of the cytoskeleton,
intercellular interactions, response to extracellular stimuli,
and regulation of cell adhesion cytokines and growth fac-
tors [11]. All these mechanisms are basic to the expression
or activation of 𝛼-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid- (AMPA-) type glutamate receptors on the
postsynaptic membrane [12], one of the main modifications
in LTP plasticity. The efficacy of neuronal synapses in many
brain areas, including the hippocampus, is controlled also
by long-lasting synaptic depression (LTD). LTD, by reduc-
ing synaptic strength, is another crucial phenomenon in
memory formation. Even if LTD was initially considered
a forgetting mechanism, recent reports suggest that LTD
plays important roles in processing new information: after
the induction of LTD by low-frequency stimulation, the
endocytosis of AMPA receptors is increased, in a Ca2+-
dependent process. AMPA receptors are then retained inside
the neuron and are stored in endosomes or alternatively
they are degraded [8].
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5. Epigenetic Mechanisms
Epigenetics is the study of changes in gene expression that
does not involve modifications in the underlying DNA
sequence: these changes may or may not be transgenera-
tionally inherited. It depends on posttranslational modifi-
cations of proteins and DNA that change the conformation
of chromatin within the nucleus. DNA is packaged into
chromatin through its wrapping around octamers of histone
proteins. Two forms of chromatin exist: heterochromatin
is characterized by condensed chromatin and subsequent
transcriptional repression, whereas euchromatin is charac-
terized by a relaxed chromatin state that allows the tran-
scriptional machinery to get access to the DNA for gene
expression.
Apart from short interfering RNAmolecules thatmediate
posttranscriptional gene silencing, two major epigenetic
modifications govern the switch between euchromatin and
heterochromatin: DNA methylation and posttranslational
modifications on histone tails [13].
DNA methylation refers to the covalent addition of a
methyl group to the C5 position of cytosine close to guanine
in CpG islands. CpG islands are short DNA sequences, often
located in the promoter region of highly expressed genes.
In CpG islands, the frequency of the CG, connected by a
phosphodiester bond (“p”), is higher than in other regions.
The levels and patterns of DNA methylation are regulated
by both DNA methyltransferases (DNMT1, DNMT3A, and
DNMT3B) and by “demethylating” enzymes, as the ten-
eleven translocation (TET) family of dioxygenases. DNMT1
is critical for the maintenance of an established methylation
signature as it methylates hemimethylated DNA during
replication; DNMT3A and 3B methylate sites irrespective of
previous methylation status, leading to “de novo” methylated
DNA, notably during gametogenesis and embryogenesis
[14].
Posttranslational modifications on histone tails consist
in the addition and removal of chemical moieties to a large
number of amino acid residues in the N-terminal tail that
are subject to covalent modifications and are dynamically
regulated by chromatin-modifying enzymes. These modifi-
cations include, but are not limited to, histone acetylation,
phosphorylation, and methylation [14] and can occur on
at least 30 different sites on histone proteins. By creating
binding sites for transcription factors, the posttranslational
modifications of histone tails play a direct regulatory role
in gene expression. Some modifications are reversible, while
others are more stable; some of them are associated with
transcriptional activation, as for acetylation, and some others,
as histone methylations, depend on the histone type and
on the specific amino acid residue for its activation or
inhibition of transcription. Many enzymes are responsible
for posttranslational modifications of histone tails: histone
methyltransferases (HLMTs) and demethylases and histone
acetyltransferase (HAT) and deacetylases (HDACs) regu-
late methylation and acetylation status on histone tails,
respectively.
6. Epigenetic Regulation of Memory Processes
One of the most intriguing aspects of memory is that remote
memories persist throughout lifespan of individuals, while
the molecules that may sustain the memory processes turn
over in few days. Some decades ago Sir Francis Crick hypoth-
esized that “memory is stored in the brain as reversible mod-
ifications to DNA and protein that alter synaptic strength”
[15]. Nowadays, it is known that epigenetic modifications of
the DNA methylation and histone tails represent those long-
lasting modifications that, influencing synaptic plasticity, can
account for memory formation and life-long duration.
The first demonstration that DNA methylation is impli-
cated in regulating memory formation refers to the DNA
methyltransferase enzymes. DNMT3A and 3B gene expres-
sion is upregulated in the adult rat hippocampus following
contextual fear conditioning, whereas their inhibition blocks
memory formation [16]; double-knockout mice for DNMT1
and 3A have impaired LTP [17]; contextual fear conditioning
in male rats decreases methylation of the memory promoting
gene reelin but increases methylation of the memory repres-
sor gene protein phosphatase 1 (PP1) [16]. Finally, DNMTs
inhibitors cause a reduction of DNA methylation in reelin
andBDNFpromoters (two important genes involved in LTP),
blocking the induction of LTP in hippocampal slice culture of
male mice and rats [18].
Some recent published observations support the involve-
ment of the histone tail modifications in controlling learn-
ing and memory processes. In neurological disorders, as
Alzheimer’s and Huntington’s diseases, and in aging, the
cognitive decline observed in patients seems to be related to
an increase of histone deacetylation that limits the expres-
sion of plasticity-related genes [19]. In mouse models of
neurodegeneration, as well as in wild-type mice, learning
and memory are facilitated by an increase of histone tail
acetylation due to HDAC inhibitors [20]. In animal models
with HAT inactivating mutations, hippocampal LTP, spatial,
contextual fear, and novel object recognition memory are
all impaired (see [1] for references). As a general concept,
memory acquisition leads to an increase in histone acetyla-
tion by modulating HAT and HDAC activity, thus resulting
in a specific pattern of gene expression. Inhibitors of HDAC
activity enhance histone acetylation, synaptic plasticity and
learning andmemory, supporting the hypothesis thatHDACs
may act as negative regulators of memory acquisition and
maintenance [21]. Interestingly, among different HDACs,
the HDAC3 (an histone deacetylase from class I) is highly
expressed in the hippocampus, cortex, and cerebellum, and
it seems to be specifically responsible for a negative memory
regulation. Recently, a new class of competitive HDAC class
I inhibitors, which allows a specific inhibition of HDAC3,
has been identified. For instance, inWistar rat’s hippocampal
slices, HDAC3 inhibition is able to restore LTP expression
in aged animals (82–84 weeks old) at levels similar to
young animals (5–7 weeks old). Moreover, the same HDAC3
inhibitors restore the ability of hippocampal synapses to
be plastic and to associate one another [22]. The changes
associated with histone acetylation occur in a gene-specific
manner throughout the chromatin: one of the best targets
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of such modifications is, for example, the promoter region
of the CREB binding protein gene (cAMP-response element-
binding protein, CBP). In a mouse model characterized
by CBP mutations and mental retardation, as well as an
impairment of long-term memory and LTP, a reduction in
chromatin acetylation was observed. By inhibiting HDAC
activity, the memory defects observed were reversed [23].
7. Neurosteroids
The term “neurosteroids” was first coined by Baulieu and
colleagues in the early 1990s in order to refer to hormonal
steroids that may be synthesized de novo in the nervous
system [24]. These neurosteroids are synthesized in most
cerebral area, hypothalamus, hippocampus, cerebral cortex,
and cerebellum, but also in the peripheral nervous system
[25, 26].
The Purkinje cells of the cerebellum, as well as the
pyramidal neurons in the CA1–CA3 regions or the granule
cells in the dentate gyrus of the hippocampus, are the major
neuronal population that actively produce neurosteroids in
the brain [27, 28]. Besides neurons, the glial cells of the
central (i.e., astrocytes and oligodendrocytes) and peripheral
(i.e., Schwann cells, SC) nervous system are also able to
synthesize neurosteroids [26, 29]. All nervous cells, indeed,
possess the synthetic machinery deputed to produce neuros-
teroids, for instance, the P450 cholesterol side-chain cleav-
age enzyme, P450SCC; 17𝛼-hydroxysteroid dehydrogenase,
17𝛼HSD; 3𝛽-hydroxysteroid dehydrogenase, 3𝛽-HSD, as well
as the enzymatic pathways converting them into neuroactive
metabolites [25]. The enzymatic complex formed by the 5𝛼-
reductase (5𝛼-R) and the 3𝛼-hydroxysteroid-dehydrogenase
(3𝛼-HSD) is rather versatile catalysing the conversion of the
native steroids, bearing the 𝛿4-3keto configuration, like pro-
gesterone, in their more active 5𝛼–3𝛼-reduced metabolites
[29–32]. Interestingly, the presence of this enzymatic complex
in the myelin forming cells, oligodendrocytes, and Schwann
cells respectively, suggests the hypothesis that the locally
formed neurosteroids might play a crucial physiological role
in these cells [26, 33]. However, the 5𝛼-reduced metabolite of
progesterone, dehydroprogesterone (DHP), is highly concen-
trated (5-fold) in differentiated oligodendrocytes, suggesting
that the acquisition of the neurosteroids biosynthetic capacity
is a marker of glial differentiation [34].
Neurosteroids regulate various functions in the cen-
tral and peripheral nervous system. Indeed, these steroids
are involved in development, neuronal plasticity, cognition,
mood control, and social and sexual behaviour, as well as in
myelination [35]. Recently, some neurosteroids were found
to be involved in the pathogenesis of severe debilitating
neuropathologies; therefore it was suggested that their mod-
ulation might be a target for neuroregenerative therapies
addressed to treat Alzheimer’s disease, multiple sclerosis,
psychiatric disorders, post-traumatic stress disorder, epilepsy,
and other neurological disorders [36, 37].
The neurosteroids actions are exerted through paracrine
and/or autocrine mechanisms. They act by interacting
with classic steroid receptors (i.e., progesterone receptor,
PR; androgen receptor, AR; estrogen receptor, ER), as
well as through nonclassic steroid receptors like the
putative membrane receptors (mPR, mAR, mER, etc.) and
some neurotransmitter receptors [38]. For instance, by rapid
action, the neurosteroidsmodulate the gamma-aminobutyric
acid (GABA), N-methyl-D-aspartate (NMDA), and 5-
hydroxytryptamine type 3 (5HT3) receptors [39–41].
The 5𝛼-pregnan-3𝛼-ol-20-one, also called tetrahydropro-
gesterone or allopregnanolone (ALLO), is the most impor-
tant neurosteroid synthesized via a bidirectional reaction,
through the action of the 5𝛼-R-3𝛼-HSD complex [25, 29].
It showed potent neurogenic properties, inducing a dose-
dependent proliferation of neural rat progenitor cells and
human stem cells [42]. Moreover, ALLO exerts important
roles also in central and peripheral glial cells [43]. ALLO
displays rapid “nongenomic” effect, which mainly involves
the potent modulation of the GABA type A (GABA-A)
receptor [40, 44], although, recently, some steroid membrane
receptors (e.g., mPR) have been identified as target for ALLO
actions in the nervous system [38]. Moreover, some ALLO’s
effects on behavioural processes involve rapid actions via
GABA-A and/or NMDA receptors but also through promis-
cuous nuclear receptor, such as the pregnane xenobiotic
receptor, PXR [45]. However, these ALLOmechanismsmight
be complementary to the classic “genomic” effects. ALLO
may be retroconverted to DHP, by enzyme 3𝛼-HSD, then
activating the classic PR; this kinetic is slower and lasts longer
time [33].
The GABA-A receptor is a member of the ligand-gated
ion channel family, permeable to chloride ions and com-
posed of five subunits drawn from a repertoire of nineteen
isoforms (i.e., 𝛼1–6, 𝛽1–3, 𝛾1–3, 𝛿, 𝜀, 𝜋, 𝜃, and 𝜌1–3) [40].
Synaptic GABA-A receptors mediate rapid phasic inhibition
of postsynaptic currents, which occurs when high levels
of GABA rapidly activate postsynaptic GABA-A receptors.
On the contrary, the activation of extrasynaptic GABA-
A receptors results on tonic inhibition, that is, observed
when continuous low levels of GABA induce a persistent
activation of extrasynaptic GABA-A receptors. The ALLO
action at GABA-A receptor is concentration-dependent.
Indeed, in the nanomolar range, ALLO acts allosterically,
enhancing the action of the natural ligand GABA, whereas,
at higher concentration (micromolar range), ALLO directly
gates the GABA-A receptor channel [40, 46]. However, it
was shown that neurosteroids may directly gate GABA-A
receptors also at lower concentration (100 nM), although
the kinetic of this receptor activation is relatively slow [47].
The GABA-A receptor modulation is enantioselective and
partially dependent upon the receptor isoforms, being 𝛼
(𝛼2–5) assembled with 𝛽3 and 𝛾2S subunits the minimum
functional composition forALLOmediated currents [40, 48].
The 𝛿 subunit potentiates the action of the 5𝛼–3𝛼-reduced
neurosteroids [49]. Whether neurosteroids might recruit
different composition of post- and extrasynaptic GABA-A
receptors is still matter of debating. However, ALLO seems
to potentiate both phasic and tonic inhibition by modulating
synaptic and extrasynaptic GABA-A receptors [50].
Interestingly, different protein kinase C (PK-C) isoforms
might phosphorylate the GABA-A receptors, influencing the
Neural Plasticity 5
sensitivity to neurosteroids [51]. Recently, the attention has
been addressed to the PKC𝜀 isoform, whose effects are
intermingled with neurosteroids [52]. PKC𝜀 may regulate
GABA-A receptor sensitivity to allosteric modulators, while
its expression may be controlled by neurosteroids [52].
8. Neurosteroids and Memory
It has become increasingly evident, in the last years, the
involvement of neurosteroids in several neurophysiological
processes; however, their role in memory represents an
interesting issue in neuroscience, deserving further investi-
gations. Data presented in the literature depict an indefinite
picture regarding the effect of progesterone and its derivatives
on memory processes. All these effects must be strictly
correlated with the hormonal milieu of the specific period of
life considered.
Different in vitro studies analysing progesterone effects
on synaptic transmission and plasticity described both the
absence of any effect on LTP in CA1 slices from 4-week-
old rats of both sexes [53] and a consistent decrease of LTP
in CA1 neurons of adult ovariectomized rat hippocampus
(while no effect on LTD) [54]. Studies performed during the
different phases of the estrous cycle suggest that, in adult,
and likely in the developing brain, progesterone contributed
to the loss of hippocampal spines and synapses observed
across the estrous cycle [55, 56]. When progesterone is
injected to ovariectomized rats, it increases spine density
in hippocampal CA1 pyramidal cells in a short time, even
if its effect is not long-lasting, showing a sharp decrease
in longer times [57]. Another controversial role for pro-
gesterone relates to its effect on cognitive performance in
women at different ages and cycle phases. Reduced levels of
estrogen and progesterone during menopause are associated
with memory impairments [58]. However, single proges-
terone administration to young women has been reported
to negatively influence cognitive performance, impairing
information processes, verbal memory, and face recognition
accuracy [59, 60]; on the contrary, progesterone treatment of
healthy adult women enhanced sustained attention, response
speed, and visuomotor coordination [61]. By the way, the
relevance of progesterone, alone or together with estrogens,
as the main factors regulating hippocampal ability to store
and retrieve memory is supported by the increased risk to
develop Alzheimer’s disease in postmenopausal women [62,
63] and by the observation that the antiprogestin RU486
administration on proestrus blocks the natural decline of
synapse density related to cycle [64].
Upon activating its own classic and/or nonclassic recep-
tors, progesterone exerts its effects on memory processes
through the modulation of many molecular pathways.
Among them, it robustly activates canonical Wnt/𝛽-catenin
signalling in the dorsal hippocampus, thus modulating hip-
pocampal memory formation [65]. Wnt signalling pathways
has been established to be crucial for adult hippocampal neu-
rons to regulate synaptic plasticity [65]. This is also strength-
ened by the observation thatWnt signalling is dysregulated in
neuropsychiatric disorder and in neurodegenerative diseases
such as Alzheimer’s disease and Down syndrome [66, 67],
while the activation of Wnt signalling can prevent the neuro-
toxic effects of beta-amyloid [68]. Wnt pathway is composed
by a group of several different proteins functioning as extra-
cellular ligands [69], secreted after different posttranslational
modifications occurring at the level of endoplasmic reticulum
[70]. In the mammalian hippocampus, Wnt signalling is
involved in neural development, axonal remodelling, and
synapse formation. Moreover, Wnt is also crucial for the
correct functioning of hippocampus in adulthood, as demon-
strated by data obtained in several mutant mice showing
memory and cognition impairment (see [65] for references).
Several groups have examined whether learning regulates
Wnt protein expression in the hippocampus. For instance, it
has been demonstrated a specific Wnt5a andWnt7 induction
in some subregions such as the granule cell layer but not in
CA3 neurons; conversely, the Wnt3 levels were not changed
[71]. Different Wnt activation in response to various learning
test (fear conditioning versus object recognition) was also
found (see [65] for references). One of the ways in which
Wnt proteinsmediatememory formation is by the interaction
with sex-steroid hormones, which are key modulators of hip-
pocampal memory formation [1]. Therefore, the activation
of the canonical Wnt/𝛽-catenin signalling by progesterone is
the understandable demonstration of the direct participation
of this neurosteroid in modulating hippocampal memory
formation.
As stated above, the main action of the progesterone
metabolite ALLO on the GABA-A receptor is inhibitory.
Indeed, in the hippocampal neurons, ALLO specifically
increases both the peak amplitude and the duration of chlo-
ride currents of GABA-A receptors [25]. Within the dentate
gyrus of the hippocampus, ALLO is actively metabolised;
thus GABAergic synapses have low sensitivity to this neuros-
teroid. In contrast, within the CA1 region of the hippocam-
pus, ALLO metabolism is less active and neurons respond
to low concentrations of ALLO. These findings suggest a
crucial role for local steroidmetabolism in regulating GABA-
A receptor-mediated inhibition in a regionally dependent
manner [72], specifically in those areas involved in memory
formation and processing.The relevance of ALLO inmemory
processing, however, is strengthened by some observations.
Indeed, it is known that ALLO increases neurogenesis and
neuronal survival, reducing apoptosis in the hippocampus
[35, 73]. ALLO also increases the density of dendritic spines,
increasing the number of mature excitatory synapsis. In
cultured hippocampal neurones, ALLO treatment induces
the formation of clusters of debrin, an actin binding protein
[74]. Debrin usually forms a unique stable actin structure in
dendritic spines of postsynaptic region of excitatory synapses,
facilitating the recruitment of other postsynaptic protein,
being a good indicator of mature synapses. The importance
of debrin in regulating hippocampal synapses is confirmed
by the evidence that debrin is decreased in the brain of
Alzheimer’s patients and of individuals with mild cognitive
impairment [75, 76].
Nevertheless, besides the clear effects of ALLO on the
molecular mechanisms involved in hippocampal synaptic
potentiation, theALLO effects on cognitive functions seem to
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be variable. Some indications suggest that ALLO may impair
learning and memory by interfering with hippocampal LTP;
some others suggest opposite effects. Pharmacological doses
of ALLO promote neurogenesis and positively influence
learning and memory [77]. In a mouse model of ammonia
hepatic encephalopathy, cognitive deficits are paralleled by
increased brain levels of ALLO; the treatment with the 5𝛼-
reductase inhibitor, finasteride, blocks the synthesis of ALLO
and LTP can be reinduced [78]. Acutely administered ALLO
inhibits learning in rats assessed with the Morris water maze
test for learning andmemory [79]. Also the bilateral microin-
fusion of ALLO into the CA1 region of dorsal hippocampus
ofmice shows impaired encoding and consolidation of object
memory [80]. On the contrary, it was shown that young rats
in proestrus and late pregnancy (i.e., reproductive conditions
associated with higher cortical ALLO levels) exhibit better
performance on the object recognition task than rats in
dioestrous or early pregnancy conditions [81]. ALLO can
also reverse the amnesic effects exerted by estradiol-benzoate
alone or plus progesterone infused into the hippocampus of
ovariectomized rats, probably through its direct modulation
of hippocampal 3𝛼-HSD activity [82].
Finally, also in vivo treatment with ALLO evidenced
controversial effects. In two transgenic mouse models for
Alzheimer’s disease, chronic ALLO treatment for one to
three months impaired learning and memory. Conversely,
in another mouse model of Alzheimer’s disease, the triple
transgenic mouse (3xTgAD), chronic ALLO administration
induced positive effects: ALLO activated neurogenesis and
oligodendrogenesis, reduced neuroinflammation and beta-
amyloid accumulation, and improved white matter markers
and cholesterol homeostasis, contemporarily with restoration
of learning and memory (see [36] for an extensive review).
9. Neurosteroids, Memory, and Epigenetics
Asmentioned above, during memory formation and mainte-
nance, synapses go through structural and functional remod-
elling, often under the influence of the hormonal milieu, thus
recruiting a lot of specific proteins, neurotransmitters, and
receptors essential for neuronal plasticity and activity. Dur-
ing aging, differences in cognitive abilities among different
individuals became evident, with some individuals exhibiting
dramatic decline (as in Alzheimer’s patients) and some others
maintaining proper brain functions until late life. One pos-
sible explanation for these important differences might arise
from a different accumulation of epigenetic changes across
the lifespan, in turn due to the “epigenetic” answer to the
molecular and hormonal status of the individual. Despite the
well-known involvement of neurosteroids and progestagens
in most of the phases of memory formation and regulation,
only few papers focused on the epigenetic involvement in
neurosteroids action on memory and cognitive abilities.
Ethanol has similar central effects of ALLO and ALLO
impairs hippocampal dependent spatial memory in ways
similar to ethanol [83]. Ethanol directly influences ALLO
release, thus modulating the GABA-A receptor [84]: for
these reasons, some data concerning the effect of epigenetic
modifications on neurosteroids-mediated pathways derive
from studies on alcohol abuse. These studies were performed
in alcohol abuser and young people used to “binge” social
drinking [85]. All individuals, consuming large quantities
of alcohol, experiment episodes of memory impairment,
known as “alcohol blackouts.” These events occur in absence
of loss of consciousness or seizure activity and represent
a kind of anterograde amnesia. Sometimes these episodes
are complete; that is, they entail deficits of memory transfer
from short-term to longer-term storage.The exact functional
mechanisms inducing alcohol impairment of hippocampal
circuits of memory are not clear. It has been suggested that
alcohol produces dose-dependent inhibition of LTP, likely
acting directly on NMDA glutamatergic synaptic currents at
higher concentrations [86, 87] or, at lower doses, increasing
GABA receptor activity.
Importantly, epigenetic modifications can be consid-
ered crucial for alcohol induced memory impairment. For
instance, different HDAC levels have been found in animals
assuming different quantities of alcohol [88]. The use of the
microarray technique evidenced a differential expression of
histone acetylase enzymes between high and low ethanol-
drinking B6-mice; the treatment with an HDAC inhibitor
was associated with an increased ethanol intake, supporting a
role for chromatinmodifications in themodulation of alcohol
preference [88].
Also the analysis of the possible epigenetic modifications
of the GABA-A receptor, mainly involved in neurosteroids
action, evidenced a specific modulation of some of the
different GABA-A receptor subunits [89]. Using a rat model,
that exhibits substantial performance variability within the
groupof aged animals (half of the aged rats performingwithin
the range of young) on a hippocampus dependent spatial
memory task, different genes showing age-associated declines
were examined. The level of these genes correlated with a
stable evaluation of memory function, measured as learning
index. All these genes were chosen because, in rat as well as in
humans, they could be directly related to neurophysiological
features of cognitive decline. Among them, Gabra5, the gene
coding for the 𝛼5 subunit of the GABA-A receptor, seems to
play a central role in age-related cognitive deficits. Gabra5
gene, which is highly and constitutively expressed in the CA3
region of the hippocampus, is located in a genomic locus that
is highly epigenetically regulated. In aged rats, characterized
by impaired CA3 inhibitory function that negatively affects
the cognitive performance, the expression of GABA-A 𝛼5
receptor subunit was reduced and the methylation degree
of the CpG islands in the promoter region of Gabra5 was
markedly increased [89].
Interestingly, also the ALLO synthesis is epigenetically
regulated. The enzyme 5𝛼-R type I (encoded by the gene
srd5a1) represents the rate-limiting step in ALLO biosynthe-
sis and plays an important role in controlling the ALLO level
in mammalian brain. In an animal model of depression, like
the isolation-reared mice, the srd5a1 gene is transcriptionally
regulated in the prefrontal cortex via the DNA methylation
of different GC rich islands in the promoter region [90].
These findings, although not directly referred to hippocampal
regions, suggest that srd5a1 genemight be an important target
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of methylating enzymes, thus regulating the availability of
ALLO for memory regulation.
10. Clinical Use of Neurosteroids
The latest advances in the fields of neurosteroids mechanisms
of action opened new perspectives for the therapeutic use of
synthetic derivatives or the promotion of endogenous neu-
rosteroid biosynthesis.The clinical potential of neurosteroids
for CNS disorder, indeed, has been extensively analysed
in the literature, suggesting their potential use in different
pathologies as epilepsy, premenstrualmood disorder, chronic
pain, alcohol dependence, traumatic brain injury, migraine
and, of course, Alzheimer’s disease [91], as well as cognitive
or memory impairment. For instance, the outcomes obtained
after ALLO treatment of the triple transgenic mouse model
of Alzheimer’s disease (3xTgAD) suggest the therapeutic
potential of ALLO for patient’s treatment. It emerged that
a single high dose of ALLO, once a week, is able to pro-
mote neurogenesis, survival of the newly generated cells,
and reduction of beta-amyloid plaques, improving cognitive
performance to normal levels [36]. Overall, ALLO meets
several criteria for suitability as a therapeutic agent, including
low molecular weight, advantageous pharmacokinetics, and
therapeutic efficacy at a subsedative dose [92]. Phase I inter-
ventional, randomized, double-blind, and placebo-controlled
clinical trial is currently underway to determine the safety
and tolerability of ALLO in Alzheimer’s disease and in mild
cognitive impairment [91].
Also progesterone has been proposed for replace-
ment therapy in neurodegeneration. In a mouse model
of Alzheimer’s disease, bringing two mutations on APP
(amyloid precursor protein) and presenilin 1, chronic proges-
terone treatment for 3–6months improved object recognition
performance [93]. Nevertheless, it should be underlined
that chronic high doses of ALLO give opposite results,
increasing performance deficits in the same mouse model
of Alzheimer’s disease [94]. Altogether, these data suggest
possible differences in response to progesterone replacement
in older rodents, which depends upon task as well as upon the
current hormone/reproductive state and/or upon the disease-
related neurodegeneration.
11. Overall Conclusions
The formation of new synapsis and the remodelling of
the existing ones are crucial phenomena to stabilize new
memories for storage and retrieval. Neurons participate to
all these processes modulating neurotransmitters release and
proteins expression both via a direct genomic action and by
epigenetic modifications. Methylation of CpG islands on the
promoter sequence of specific genes and the posttranslation
modifications of histone tails determine the chromatin to be
condensed or relaxed, thus governing synaptic strength and
the formation of new neuronal connections basic to allow
memories to persist throughout our life. During aging and as
a consequence of neurodegenerative disease, Alzheimermost
of all, memory is strongly impaired: despite the wide amount
of publications concerning neurodegeneration, only some
aspects of this cognitive decline have been completely under-
stood. Neurosteroids play a consistent role in modulating
different phases of memory formation, with ALLO, acting on
GABA-A receptor, being the main effector. Inconclusive data
on ALLO therapies for Alzheimer patients are available up
to now, but the clinical trial today at study might offer some
new opportunities. Finally, as histone deacetylation seems to
be a marker of age-related cognitive decline, the new class
of competitive histone deacetylase (HDAC) class I inhibitors,
which allows a specific inhibition ofHDAC3,might represent
a new powerful therapeutic tool.
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